These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34847495)

  • 1. Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents.
    Zheng H; Dai Q; Yuan Z; Fan T; Zhang C; Liu Z; Chu B; Sun Q; Chen Y; Jiang Y
    Bioorg Med Chem; 2022 Jan; 53():116524. PubMed ID: 34847495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
    Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
    Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y
    Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.
    Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A
    ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo Anticancer Potential of Hydroxamic Acid Derivatives.
    Li H; Gong Y; Zhong Q
    Curr Top Med Chem; 2021; 21(19):1737-1755. PubMed ID: 34392823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
    Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
    Liu R; Wang J; Tang W; Fang H
    Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities.
    Yang F; Han L; Zhao N; Yang Y; Ge D; Zhang H; Chen Y
    Future Med Chem; 2020 Apr; 12(8):655-672. PubMed ID: 32202140
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
    Lee S; Wang SW; Yu CL; Tai HC; Yen JY; Tuan YL; Wang HH; Liu YT; Chen SS; Lee HY
    Bioorg Med Chem; 2021 Nov; 50():116454. PubMed ID: 34634618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.